Please enable JavaScript to continue using this application.

Compare $KYMR vs $PTGX | Chartloom

Compare

$KYMR vs $PTGX

Kymera Therapeutics Inc · Protagonist Therapeutics Inc

KYMR

Kymera Therapeutics Inc

PTGX

Protagonist Therapeutics Inc

Compare $KYMR vs $PTGX

Comparing Kymera Therapeutics Inc and Protagonist Therapeutics Inc

KYMRKymera Therapeutics Inc

PTGXProtagonist Therapeutics Inc

KYMRKymera Therapeutics Inc

Market cap

$9.25B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

456.91x

Rev growth (TTM)

134.8%

YTD performance

54.5%

52W performance

99.7%

FCF yield

-2.6%

PTGXProtagonist Therapeutics Inc

Market cap

$9.24B

P/E (TTM)

123.10x

Forward P/E (NTM)

77.71x

Forward P/S (NTM)

23.74x

Rev growth (TTM)

34.8%

YTD performance

64.9%

52W performance

120.1%

FCF yield

1.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KYMR

PTGX

Detailed metrics comparison

KYMR

Kymera Therapeutics Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

KYMR$9.25B

PTGX$9.24B

Enterprise Value

KYMR$9.12B

PTGX$8.82B

Price

KYMR$112.40

PTGX$143.73

P/E Ratio

KYMRN/A

PTGX123.10x

P/S Ratio

KYMR88.06x

PTGX32.78x

EV/Sales

KYMR86.90x

PTGX31.29x

EV/EBITDA

KYMR0.00x

PTGX140.17x

P/B Ratio

KYMR5.92x

PTGX10.77x

P/FCF Ratio

KYMRN/A

PTGX70.79x

EV/FCF

KYMR-38.34x

PTGX67.57x

PEG Ratio

KYMRN/A

PTGX2.95x

Forward P/E (NTM)

KYMRN/A

PTGX77.71x

Forward P/S (NTM)

KYMR456.91x

PTGX23.74x

Revenue (TTM)

KYMR$105M

PTGX$282M

Revenue Growth (YoY)

KYMR134.8%

PTGX34.8%

Forward Rev Growth

KYMR-62.1%

PTGX-70.6%

Gross Margin (TTM)

KYMR0.0%

PTGX0.0%

Operating Margin (TTM)

KYMR0.0%

PTGX20.7%

EBITDA Margin (TTM)

KYMR-322.0%

PTGX21.2%

Net Margin (TTM)

KYMR-285.3%

PTGX29.4%

FCF Margin (TTM)

KYMR-226.6%

PTGX46.3%

Net Income (TTM)

KYMR$-300M

PTGX$83M

FCF (TTM)

KYMR$-238M

PTGX$131M

EPS (TTM)

KYMR-$3.05

PTGX$1.17

ROE (TTM)

KYMR-2150.0%

PTGX12.0%

ROA (TTM)

KYMR-1946.0%

PTGX11.2%

ROIC (TTM)

KYMR-2145.0%

PTGX12.0%

Cash

KYMR$124M

PTGX$420M

Debt

KYMR$2M

PTGX$0

Net Cash/Debt

KYMR$122M

PTGX$420M

Current Ratio (TTM)

KYMR10.34x

PTGX21.71x

Quick Ratio (TTM)

KYMR9.97x

PTGX21.58x

Debt/Equity (TTM)

KYMR0.00x

PTGX0.00x

Debt/Assets (TTM)

KYMR0.0%

PTGX0.0%

Interest Coverage (TTM)

KYMRN/A

PTGXN/A

Net Debt/EBITDA (TTM)

KYMR0.00x

PTGX0.00x

Beta

KYMR2.05

PTGX1.19

52W Performance

KYMR99.7%

PTGX120.1%

YTD Performance

KYMR54.5%

PTGX64.9%

% from 52W High

KYMR-13.6%

PTGX-10.6%

% from 52W Low

KYMR103.4%

PTGX119.2%

Asset Turnover (TTM)

KYMR0.07x

PTGX0.38x

FCF Yield (TTM)

KYMR-2.6%

PTGX1.4%

Earnings Yield (TTM)

KYMR-3.2%

PTGX0.9%

Dividend Yield (TTM)

KYMRN/A

PTGXN/A

Rule of 40

KYMR-91.8

PTGX81.1

EV/GP/RG

KYMRN/A

PTGXN/A

Ticker research

View KYMR research View PTGX research

Metric	KYMR Kymera Therapeutics Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$9.25B	$9.24B
Enterprise Value	$9.12B	$8.82B
Price	$112.40	$143.73
P/E Ratio	N/A	123.10x
P/S Ratio	88.06x	32.78x
EV/Sales	86.90x	31.29x
EV/EBITDA	0.00x	140.17x
P/B Ratio	5.92x	10.77x
P/FCF Ratio	N/A	70.79x
EV/FCF	-38.34x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	N/A	77.71x
Forward P/S (NTM)	456.91x	23.74x
Revenue & Growth
Revenue (TTM)	$105M	$282M
Revenue Growth (YoY)	134.8%	34.8%
Forward Rev Growth	-62.1%	-70.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	20.7%
EBITDA Margin (TTM)	-322.0%	21.2%
Net Margin (TTM)	-285.3%	29.4%
FCF Margin (TTM)	-226.6%	46.3%
Net Income (TTM)	$-300M	$83M
FCF (TTM)	$-238M	$131M
EPS (TTM)	-$3.05	$1.17
ROE (TTM)	-2150.0%	12.0%
ROA (TTM)	-1946.0%	11.2%
ROIC (TTM)	-2145.0%	12.0%
Financial Health
Cash	$124M	$420M
Debt	$2M	$0
Net Cash/Debt	$122M	$420M
Current Ratio (TTM)	10.34x	21.71x
Quick Ratio (TTM)	9.97x	21.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	1.19
52W Performance	99.7%	120.1%
YTD Performance	54.5%	64.9%
% from 52W High	-13.6%	-10.6%
% from 52W Low	103.4%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.38x
FCF Yield (TTM)	-2.6%	1.4%
Earnings Yield (TTM)	-3.2%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-91.8	81.1
EV/GP/RG	N/A	N/A
Ticker research	View KYMR research	View PTGX research

Valuation

P/E Ratio

PTGX

123.10x

P/S Ratio

PTGX

32.78x

KYMR

88.06x

EV/FCF

KYMR

-38.34x

PTGX

67.57x

Growth & revenue

Revenue Growth TTM

KYMR

134.8%

PTGX

34.8%

Forward Revenue Growth

KYMR

-62.1%

PTGX

-70.6%

Profitability & performance

Gross Margin

KYMR

0.0%

PTGX

0.0%

ROE

PTGX

12.0%

KYMR

-2150.0%

FCF Yield %

PTGX

1.4%

KYMR

-2.6%

52-Week Performance

PTGX

120.1%

KYMR

99.7%

Detailed metrics comparison

KYMR

Kymera Therapeutics Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

KYMR$9.25B

PTGX$9.24B

Enterprise Value

KYMR$9.12B

PTGX$8.82B

Price

KYMR$112.40

PTGX$143.73

P/E Ratio

KYMRN/A

PTGX123.10x

P/S Ratio

KYMR88.06x

PTGX32.78x

EV/Sales

KYMR86.90x

PTGX31.29x

EV/EBITDA

KYMR0.00x

PTGX140.17x

P/B Ratio

KYMR5.92x

PTGX10.77x

P/FCF Ratio

KYMRN/A

PTGX70.79x

EV/FCF

KYMR-38.34x

PTGX67.57x

PEG Ratio

KYMRN/A

PTGX2.95x

Forward P/E (NTM)

KYMRN/A

PTGX77.71x

Forward P/S (NTM)

KYMR456.91x

PTGX23.74x

Revenue (TTM)

KYMR$105M

PTGX$282M

Revenue Growth (YoY)

KYMR134.8%

PTGX34.8%

Forward Rev Growth

KYMR-62.1%

PTGX-70.6%

Gross Margin (TTM)

KYMR0.0%

PTGX0.0%

Operating Margin (TTM)

KYMR0.0%

PTGX20.7%

EBITDA Margin (TTM)

KYMR-322.0%

PTGX21.2%

Net Margin (TTM)

KYMR-285.3%

PTGX29.4%

FCF Margin (TTM)

KYMR-226.6%

PTGX46.3%

Net Income (TTM)

KYMR$-300M

PTGX$83M

FCF (TTM)

KYMR$-238M

PTGX$131M

EPS (TTM)

KYMR-$3.05

PTGX$1.17

ROE (TTM)

KYMR-2150.0%

PTGX12.0%

ROA (TTM)

KYMR-1946.0%

PTGX11.2%

ROIC (TTM)

KYMR-2145.0%

PTGX12.0%

Cash

KYMR$124M

PTGX$420M

Debt

KYMR$2M

PTGX$0

Net Cash/Debt

KYMR$122M

PTGX$420M

Current Ratio (TTM)

KYMR10.34x

PTGX21.71x

Quick Ratio (TTM)

KYMR9.97x

PTGX21.58x

Debt/Equity (TTM)

KYMR0.00x

PTGX0.00x

Debt/Assets (TTM)

KYMR0.0%

PTGX0.0%

Interest Coverage (TTM)

KYMRN/A

PTGXN/A

Net Debt/EBITDA (TTM)

KYMR0.00x

PTGX0.00x

Beta

KYMR2.05

PTGX1.19

52W Performance

KYMR99.7%

PTGX120.1%

YTD Performance

KYMR54.5%

PTGX64.9%

% from 52W High

KYMR-13.6%

PTGX-10.6%

% from 52W Low

KYMR103.4%

PTGX119.2%

Asset Turnover (TTM)

KYMR0.07x

PTGX0.38x

FCF Yield (TTM)

KYMR-2.6%

PTGX1.4%

Earnings Yield (TTM)

KYMR-3.2%

PTGX0.9%

Dividend Yield (TTM)

KYMRN/A

PTGXN/A

Rule of 40

KYMR-91.8

PTGX81.1

EV/GP/RG

KYMRN/A

PTGXN/A

Ticker research

View KYMR research View PTGX research

Metric	KYMR Kymera Therapeutics Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$9.25B	$9.24B
Enterprise Value	$9.12B	$8.82B
Price	$112.40	$143.73
P/E Ratio	N/A	123.10x
P/S Ratio	88.06x	32.78x
EV/Sales	86.90x	31.29x
EV/EBITDA	0.00x	140.17x
P/B Ratio	5.92x	10.77x
P/FCF Ratio	N/A	70.79x
EV/FCF	-38.34x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	N/A	77.71x
Forward P/S (NTM)	456.91x	23.74x
Revenue & Growth
Revenue (TTM)	$105M	$282M
Revenue Growth (YoY)	134.8%	34.8%
Forward Rev Growth	-62.1%	-70.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	20.7%
EBITDA Margin (TTM)	-322.0%	21.2%
Net Margin (TTM)	-285.3%	29.4%
FCF Margin (TTM)	-226.6%	46.3%
Net Income (TTM)	$-300M	$83M
FCF (TTM)	$-238M	$131M
EPS (TTM)	-$3.05	$1.17
ROE (TTM)	-2150.0%	12.0%
ROA (TTM)	-1946.0%	11.2%
ROIC (TTM)	-2145.0%	12.0%
Financial Health
Cash	$124M	$420M
Debt	$2M	$0
Net Cash/Debt	$122M	$420M
Current Ratio (TTM)	10.34x	21.71x
Quick Ratio (TTM)	9.97x	21.58x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	1.19
52W Performance	99.7%	120.1%
YTD Performance	54.5%	64.9%
% from 52W High	-13.6%	-10.6%
% from 52W Low	103.4%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.38x
FCF Yield (TTM)	-2.6%	1.4%
Earnings Yield (TTM)	-3.2%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-91.8	81.1
EV/GP/RG	N/A	N/A
Ticker research	View KYMR research	View PTGX research